IDS and mucopolysaccharidosis type 2: Unfortunately, after many years of extensive review and regulatory discussions, the idursulfase‐IT data were found to be insufficient to meet the evidentiary standard to support regulatory filings for the use of idursulfase‐IT in the treatment of MPS II.